Home » OTS, FUSO LAUNCH TRIAL OF OTS102
OTS, FUSO LAUNCH TRIAL OF OTS102
OncoTherapy Science (OTS) and Fuso Pharmaceutical have announced that Japan's Pharmaceuticals and Medical Devices Agency has accepted a notification of the Phase I clinical trial plan of OTS102, an angiogenesis inhibitor currently under development by OTS.
Accordingly, the companies plan to conclude a contract with medical institutions and begin registering patients in the trial. OTS102, which consists of VEGF-R2 protein, can inhibit blood vessels from growing out of a solid tumor.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May